GSK (LON:GSK) Insider Wendy Becker Acquires 3,334 Shares

GSK plc (LON:GSK) insider Wendy Becker bought 3,334 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The stock was bought at an average price of GBX 2,219 per share, with a total value of £73,981.46.

Wendy Becker also recently made the following trade(s):

• On Friday, December 19th, Wendy Becker purchased 441 shares of GSK stock. The shares were bought at an average price of GBX 1,809 per share, for a total transaction of £7,977.69.

GSK Price Performance

GSK stock opened at GBX 2,223.16 on Friday. The business’s 50-day moving average is GBX 1,923 and its two-hundred day moving average is GBX 1,722.15. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The firm has a market capitalization of £89.70 billion, a P/E ratio of 16.72, a P/E/G ratio of 1.24 and a beta of 0.31. GSK plc has a 1 year low of GBX 1,242.50 and a 1 year high of GBX 2,282.

GSK (LON:GSK) last released its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Analysts anticipate that GSK plc will post 175.980975 earnings per share for the current fiscal year.

GSK News Roundup

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Investor confidence boost — IBD upgraded GSK’s ADR, a technical/fundamental endorsement that can attract momentum and retail buying. GSK ADR earns IBD stock rating upgrade
• Positive Sentiment: Insider buying — independent director Wendy Becker purchased 3,334 shares at ~GBX 2,219, signaling management/board conviction. Insider purchases often support sentiment. GSK Director Wendy Becker Increases Stake with Share Purchase
• Positive Sentiment: Ongoing buybacks — GSK repurchased 470,000 shares (~£10.5m) recently, modestly supporting EPS and indicating capital return. GSK lifts treasury stake with latest £10.5m share buyback
• Positive Sentiment: Clinical/commercial upside — a real‑world study reported AREXVY (RSV vaccine) is associated with lower risks of heart attack, stroke and severe COPD/asthma exacerbations, which could bolster uptake and long‑term revenue. GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks
• Positive Sentiment: R&D partnerships — GSK struck multi‑year collaborations with Jackson Laboratory / NYSCF to advance human cellular models and neurodegenerative research, strengthening its pipeline in high‑value areas. These are longer‑term positives for drug discovery. GSK strikes 5-year deal with Jackson Laboratory
• Neutral Sentiment: Trading activity — options activity has spiked on NYSE listings, indicating speculative interest and short‑term volatility rather than a directional fundamental change. GSK Sees Options Surge in NYSE Composite
• Neutral Sentiment: Analyst/market discussion — some market pieces question whether GSK’s recent rally limits upside, which can cool momentum even amid positive fundamentals. Is It Too Late To Consider GSK After Its Strong Share Price Rally?
• Negative Sentiment: Insider selling — former CEO Luke Miels sold 15,579 shares recently; large director/exec sales can weigh on sentiment even if they’re for personal reasons. Luke Miels Sells 15,579 Shares of GSK Stock

Wall Street Analyst Weigh In

A number of analysts have issued reports on GSK shares. UBS Group reaffirmed a “neutral” rating and set a GBX 1,940 price target on shares of GSK in a report on Friday, January 23rd. Berenberg Bank raised their target price on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research report on Monday, November 24th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a research note on Wednesday, January 7th. Finally, Shore Capital Group reissued a “buy” rating and set a GBX 2,300 price objective on shares of GSK in a report on Wednesday, February 4th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, GSK presently has an average rating of “Hold” and a consensus price target of GBX 1,917.86.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.